Literature DB >> 15217713

Impaired GATA-1 expression and myelofibrosis in an animal model.

Alessandro M Vannucchi1, Lucia Bianchi, Francesco Paoletti, Viviana Di Giacomo, Giovanni Migliaccio, Anna Rita Migliaccio.   

Abstract

The genetic lesion(s) underlying chronic idiopathic myelofibrosis, as well as the mechanisms leading to the typical fibro-osteosclerotic changes of the bone marrow microenvironment, are still undefined. Recently, animal models of the disease have been described. We will briefly review the characteristics of these models, the thrombopoietin-overexpressing mice and the GATA-1(low) mice (mice deficient for GATA-1 expression in megakaryocytes), and illustrate how they provided insights into pathogenetic mechanisms of myelofibrosis, with special regard to the role of abnormal megakaryocyte proliferation and maturation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15217713     DOI: 10.1016/j.patbio.2004.02.008

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  5 in total

1.  More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders.

Authors:  David P Steensma; Animesh Pardanani; William S Stevenson; Rosemary Hoyt; Hiu Kiu; Andrew P Grigg; Jeff Szer; Surender Juneja; Douglas J Hilton; Warren S Alexander; Andrew W Roberts
Journal:  Blood       Date:  2006-02-15       Impact factor: 22.113

2.  Captopril mitigates splenomegaly and myelofibrosis in the Gata1low murine model of myelofibrosis.

Authors:  Seth J Corey; Jyoti Jha; Elizabeth A McCart; William B Rittase; Jeffy George; Joseph J Mattapallil; Hrishikesh Mehta; Mungunsukh Ognoon; Michelle A Bylicky; Thomas A Summers; Regina M Day
Journal:  J Cell Mol Med       Date:  2018-07-04       Impact factor: 5.310

3.  G6b-B regulates an essential step in megakaryocyte maturation.

Authors:  Isabelle C Becker; Zoltan Nagy; Georgi Manukjan; Melanie Haffner-Luntzer; Maximilian Englert; Tobias Heib; Timo Vögtle; Carina Gross; Richa Bharti; Sascha Dietrich; Kristina Mott; Johannes Heck; Sebastian Stegmaier; Anke Baranowsky; Thorsten Schinke; Nicolas Schlegel; Tobias Heckel; David Stegner; Irina Pleines; Anita Ignatius; Harald Schulze; Bernhard Nieswandt
Journal:  Blood Adv       Date:  2022-05-24

Review 4.  Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin.

Authors:  Lei Qin; Nian Liu; Chao-le-Meng Bao; Da-Zhi Yang; Gui-Xing Ma; Wei-Hong Yi; Guo-Zhi Xiao; Hui-Ling Cao
Journal:  Acta Pharmacol Sin       Date:  2022-07-27       Impact factor: 7.169

5.  GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.

Authors:  Naery Yang; Sholhui Park; Min Sun Cho; Miae Lee; Ki Sook Hong; Yeung Chul Mun; Chu Myong Seong; Hee Jin Huh; Jungwon Huh
Journal:  Ann Lab Med       Date:  2018-07       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.